In humans, the A1 (T) allele of the dopamine (DA) D2 receptor/ankyrin repeat and kinase domain containing 1 (DRD2/ANKK1) TaqIA (rs1800497) single nucleotide polymorphism has been associated with reduced striatal DA D2/D3 receptor (D2/D3R) availability. However, radioligands used to estimate D2/D3R are displaceable by endogenous DA and are nonselective for D2R, leaving the relationship between TaqIA genotype and D2R specific binding uncertain. Using the positron
| I N T R O D U C T I O N
The role of striatal dopamine (DA) signaling in substance abuse and psychiatric disorders has yet to be fully characterized. Postiron emission tomography (PET) studies with displaceable DA D2/D3 receptor (D2/D3R) radioligands show that low striatal D2/D3R availability may be associated with impulsivity (Clark et al., 2012) , addiction to alcohol (Martinez et al., 2005; Volkow et al., 1996) , substance abuse (Fehr et al., 2008; Martinez et al., 2004; Volkow et al., 1990 Volkow et al., , 2001 , and obesity (de Weijer et al., 2011; Haltia et al., 2007; Wang et al., 2001) whereas high D2/D3R availability has been associated with risk for schizophrenia (Laruelle, 1998) , although this finding has not been replicated (Howes et al., 2012; Kambeitz, Abi-Dargham, Kapur, & Howes, 2014) . Similarly, the A1 (T) allele of the single nucleotide polymorphism (SNP) TaqIA (rs1800497), located in the ankyrin repeat and kinase domain containing 1 (ANKK1) 10 kb downstream from the DA D2 receptor (DRD2) gene (Grandy et al., 1989) , is associated with addictive behavior including gambling (Comings et al., 1996) , substance abuse (Chen et al., 2004; Messas et al., 2005; Noble et al., 1993; Persico, Bird, Gabbay, & Uhl, 1996; Lawford et al., 2000) , and binge eating (Davis et al., 2012) and with obesity (Duran-Gonzalez et al., 2011; Noble et al., 1994; Spitz, 2000; Stice, Spoor, Bohon, & Small, 2008; Thomas, Critchley, Tomlinson, Cockram, & Chan, 2001 ) while the A2 (C) allele is associated with risk for schizophrenia (Arab & Elhawary, 2015; Dubertret et al., 2010; Parsons et al., 2007) .
Individual variability in striatal D2/D3R availability is significantly heritable, as detected by a twin study (Borg et al., 2015) . In addition, the similar pattern of associations between DRD2/ANKK1 TaqIA variants and D2/D3R availability with psychiatric and drug abuse risk has led to speculation that DRD2's role in these disorders may be mediated by D2R. Indeed, the A1 allele of the DRD2/ANKK1 TaqIA A1 variant has been associated with lower striatal D2/D3R availability relative to the A2 allele in several postmortem (Gluskin & Mickey, 2016; Noble, Blum, Ritchie, Montgomery, & Sheridan, 1991; Ritchie & Noble, 2003; Thompson et al., 1997) and in vivo PET studies (Gluskin & Mickey, 2016; Hirvonen et al., 2009a; Jonsson et al., 1999; Pohjalainen et al., 1998; Savitz et al., 2013) . However, a SPECT study (Laruelle, Gelernter, & Innis, 1998) and two PET studies (Brody et al., 2006; Wagner et al., 2014) did not find this association, likely due to study of diseased populations (Gluskin & Mickey, 2016) . To date, studies have used PET radioligands (e.g. [ 11 C]raclopride (Brody et al., 2006; Hirvonen et al., 2009a; Jonsson et al., 1999; Pohjalainen et al., 1998; Savitz et al., 2013; Thompson et al., 1997; Wagner et al., 2014) (Noble et al., 1991; Ritchie & Noble, 2003) ) and the SPECT radioligand does not undergo agonist-mediated internalization, is resistant to displacement by endogenous DA, and is selective for D2R over D3R by 200-fold (Karimi et al., 2011; Moerlein, Perlmutter, Markham, & Welch, 1997 The current studies examined whether DRD2/ANKK1 TaqIA allele status is associated with striatal D2R specific binding. We analyzed data from two independent studies that employed PET with [ TaqIA variant. Based on previous evidence (Gluskin & Mickey, 2016; Jonsson et al., 1999; Pohjalainen et al., 1998; Savitz et al., 2013) , we hypothesized that A1 allele carriers (A11) would have lower striatal D2R binding than individuals homozygous for A2 (A12). We also performed meta-analyses to generate pooled effect sizes that reflect the ability of DRD2/ANKK1 TaqIA allele status to predict D2R specific binding across striatal regions.
| MATERIALS A ND METHODS

| Participants
For Study 1, participants were recruited for a study of obesity and D2R from the St. Louis region via a research volunteer database, flyers, and word of mouth. Data from these individuals regarding the relationship between obesity and striatal D2R were previously presented (Eisenstein et al., 2013 (Eisenstein et al., , 2015a (Eisenstein et al., , 2015b . Individuals with obesity (n 5 24) and without obesity (n 5 20), aged 18 to 40 years, were eligible for the study based on strict inclusion and exclusion criteria (Eisenstein et al., 2013) . Exclusion criteria included a diagnosis of type 2 diabetes (based on oral glucose tolerance test), history of psychiatric or neurological diagnoses, tobacco, or illegal substance use, and dopaminergic medication use. Handedness was obtained by self-report. A subset of participants (24 obese and 16 nonobese)
were genotyped for the DRD2/ANKK1 TaqIA (rs1800497) polymorphism and completed PET neuroimaging. Some participants were not genotyped because we did not have biological specimens from which to extract DNA (n 5 4).
For Study 2, healthy controls (HC; n 5 10), siblings of individuals with schizophrenia (SIB; n 5 10), and individuals with schizophrenia or schizoaffective disorder (SCZ; n 5 3) were recruited for a study of schizophrenia, reward behavior, and D2R. Participants (age range 18-50 years) were recruited by word of mouth, flyers, and during recruit- 
| Magnetic resonance imaging and PET imaging
For Study 1, the methods used to obtain magnetic resonance image (MRI) and PET scans were reported (Eisenstein et al., 2013) . Briefly, MRI scans were obtained on the Siemens MAGNETOM Tim Trio 3T using a three-dimensional MP-RAGE sequence (sagittal orientation, TR 5 2,400 ms, TE 5 3.16 ms, flip angle 5 88, slab thickness 5 176 mm, FOV 5 256 3 256 mm, voxel dimensions 5 1 3 1 3 1 mm) and PET scans were obtained on the Siemens CTI ECAT/EXACT HR1. The radioligand [ 11 C]NMB was prepared using an automated system previously described (Moerlein, Perlmutter, Welch, 2004; Moerlein et al., 2010) . Radiochemical purity of [ MR and PET image processing has been previously described in detail (Eisenstein et al., 2012 (Eisenstein et al., , 2013 . A priori regions of interest (ROIs) including dorsal and ventral areas of the striatum (putamen, caudate, and nucleus accumbens (NAc)) were identified using FreeSurfer (Fischl et al., 2002) on the MP-RAGE MR images for each participant.
Dynamic PET images were co-registered to each other and to the MP-RAGE image for each individual as previously described (Eisenstein et al., 2012) . ROIs and the cerebellar reference region were resampled in the same atlas space and decay-corrected tissue activity curves were obtained from the dynamic PET data for every ROI. For both studies, a priori regions of interest (ROIs) included putamen, caudate, nucleus accumbens (NAc), dorsal striatum (putamen 1 caudate), and total striatum (putamen 1 caudate 1 NAc). D2R nondisplaceable binding potentials (BP ND s) were obtained for each ROI with the Logan graphical method with whole cerebellum as a reference region (Antenor-Dorsey, Markham, Moerlein, Videen, & Perlmutter, 2008) . D2R BP ND s for each ROI were averaged across left and right hemispheres to reduce the number of comparisons for primary analyses and because we did not have a priori hypotheses about laterality effects.
| Meta-analyses
Cohen's d effect sizes were estimated for Study 1 and Study 2. To obtain pooled effect sizes for differences in D2R specific binding between A11 and A12, meta-analyses were performed including Study 1 and Study 2 for each ROI.
| Primary statistical analyses
Data from each study was analyzed separately due to use of different PET scanners. Hierarchical linear regressions were used to determine whether DRD2/ANKK1 TaqIA allele status predicted D2R BP ND for each ROI.
Step 1 Weighted mean difference (MD) with the corresponding 95% CI was reported as the pooled effect size. I 2 and v 2 tests determined heterogeneity and p < .10 was considered significant. Since heterogeneity did not exist across studies (I 2 54%, p .14), a fixed-effects model was used to calculate pooled effect size. Forest plots were generated with p < .05 considered significant.
| R E S U L T S 3.1 | Participants
In Study 1, 40 individuals were genotyped for the DRD2/ANKK1 TaqIA (rs1800497) polymorphism. For unknown reasons, one obese, A1/A2 participant's D2R binding values were greater than 2.5 (2.6-3.1 across all ROIs) standard deviations above the A11 group mean and was thus excluded from analyses. Only one individual was homozygous for the A1 allele. Therefore, this participant's data was pooled with that from A1/A2 individuals for comparisons to individuals homozygous for A2.
The final dataset included 14 obese and 7 nonobese A11 and 9 obese and 9 nonobese A12. Step 1 Step 2 Step 3 Step 4 Nucleus accumbens (N 5 39)
Step 1 Step 2 Step 3 Step 4 Step 1 Step 2 Step 3 Step 4 Figure 1a ,b, Table 2 ) and in dorsal striatum at trend-level significance (p 5 .09, Table 2 ). DRD2/ANKK1 TaqIA allele status and D2R binding in putamen and caudate were not significantly related (both b 0.23, p 5 .11, Table 2 ). Across ROIs, D2R binding was lower in A11 relative to A12 by 5-8%). Neither a main effect of obesity group (obese/nonobese) nor an interactive effect with DRD2/ANKK1
TaqIA allele status was observed for D2R binding in any ROI (all p .13, Table 2 ). D2R BP ND means (SDs), percent difference in binding, and estimated Cohen's d effect sizes are presented in Table 3 .
In Study 2, DRD2/ANKK1 TaqIA allele status predicted D2R binding in total striatum, dorsal striatum, and putamen (all b 0.41, p .05; all R 2 0.11; Figure 1c ,d, Table 4 ). DRD2/ANKK1 TaqIA allele status did not significantly predict caudate or NAc D2R binding (both p .09, Table 3 .
| Meta-analyses
The pooled analyses of Study 1 and Study 2 revealed that D2R specific binding was significantly lower in A11 relative to A12 across all striatal ROIs (Figures 2 and 3) .
| DISCUSSION
We show in two independent studies that DRD2/ANKK1 TaqIA (rs1800497) allele status predicts striatal D2R specific binding in FIG URE 2 Forest plots of the pooled effect sizes for reduced (a) striatal and (b) dorsal D2R specific binding in A11 relative to A12 individuals according to study. In both cases, the pooled effect sizes were significant. Size of square is proportional to weight of mean. CI, confidence interval; df, degrees of freedom; IV, inverse variance (statistical method). Step 1 Step 2 Step 3 Step obese or controls vs. psychosis). Our findings extend previous reports linking DRD2/ANKK1 TaqIA allele status to D2/D3R availability in postmortem striatal tissue (Gluskin & Mickey, 2016; Noble et al., 1991; Ritchie & Noble, 2003; Thompson et al., 1997) and in vivo molecular imaging data in humans (Gluskin & Mickey, 2016; Hirvonen et al., 2009a; Jonsson et al., 1999; Pohjalainen et al., 1998; Savitz et al., 2013) . Pooled effect sizes, or weighted mean differences, for total and dorsal striatal differences in D2R specific binding between A11 and A12 were larger (0.84, 0.69) than that calculated for in vivo D2/D3R availability studies (0.57; Gluskin & Mickey, 2016) . However, the 95% confidence intervals for total striatum (0.30, 1.37) in our D2R study overlaps with that of D2/D3R availability studies (0.27, 0.87; Gluskin & Mickey, 2016) , indicating that our effect size estimates are consistent with those of previous D2/D3R studies. Of note, DRD2/ANKK1 TaqIA status accounted for 5 to 14% of the variance in striatal D2R binding (Tables 2 and 4 ), comparable to 7% of striatal D2/D3R availability in previous in vivo PET studies (Gluskin & Mickey, 2016 Our results contrast with those of Laruelle, Gelernter, & Innis (1998) , in which D2/D3R availability did not differ between A11 and A12. However, that study used SPECT, which has lower resolution than PET. In addition, a large proportion of the sample in Laruelle et al. (1998) were patients with schizophrenia, some of whom may have been taking neuroleptics that increase D2/D3R availability in schizophrenia (Silvestri et al., 2000) . Two other previous studies did not find differences in baseline D2/D3R availability between A11 and A12 (Brody et al., 2006; Wagner et al., 2014) but these included diseased populations including smokers (Brody et al., 2006) and traumatic brain injured individuals (Wagner et al., 2014) . Variability in D2/D3R availability measurement due to small sample sizes may have contributed to null findings in these studies. In addition, recent meta-analysis of these D2/D3R studies revealed that the difference in D2/D3R availability between A11 and A12 is robust in healthy individuals but not in diseased individuals (Gluskin & Mickey, 2016) , suggesting that disease may modify this association. Intriguingly, extrastriatal D2/D3R availability, as measured by PET with [ 11 C]FLB457, was elevated in A11 relative to A12 (Hirvonen et al., 2009b) There was no significant effect of group on D2R binding in either study. Nor did group interact with TaqIA allele status to predict striatal D2R binding. We have not previously found there to be differences in striatal D2R between an overlapping sample of individuals without obesity and with obesity (Eisenstein et al., 2013) . In the case of study 2, the SCZ group was not large enough to fairly compare striatal D2R
binding to HC and SIB. Neither study is truly large enough to investigate the interaction between group and allele status on striatal D2R
binding. Therefore, caution should be used in interpreting the null results of these studies. Rather, we emphasize our main finding that when group (and other covariates) was controlled for, striatal D2R Size of square is proportional to weight of mean. CI, confidence interval; df, degrees of freedom; IV, inverse variance (statistical method).
binding was lower in A11 individuals compared with A12 individuals in two independent studies.
The mechanism by which the TaqIA variant, which resides in a noncoding region 10 kb downstream from the DRD2 gene (Grandy et al., 1989) , influences D2R binding remains unknown. Strong linkage disequilibrium with one or more functional variants, including the DRD2 intronic SNPs rs2283265 and rs1076560 (Zhang et al., 2007) and the ANKK1 missense SNP rs7118900 (Hoenicka et al., 2010) , may influence receptor expression (Comings et al., 1991; O'Hara et al., 1993) . A likely candidate is the C957T variant (rs6277), which disrupts mRNA stability and synthesis of D2R (Duan et al., 2003) and is in linkage disequilibrium with the TaqIA SNP (Duan et al., 2003) . The C957T variant relates to decreased D2/D3R availability as measured in vivo with [
11 C]raclopride (Hirvonen et al., 2004) . However, the C957T variant appears to affect striatal D2/D3R availability by changing receptor affinity while the TaqIA A1 polymorphism contributes to variability in D2/D3R availability by changing B max (Hirvonen et al., 2009a Limitations of the currently described studies include small sample sizes and heterogeneity of sample composition. Therefore, our power to detect group differences in D2R binding or allele status and interactions between group and allele status was low. Differences in PET scanner characteristics precluded combining data from the two studies for analyses, which would have provided more power. Nonetheless, we still detected relationships between DRD2/ANKK1 allele status and striatal D2R specific binding in the predicted direction and with small to large effect sizes, independent of group membership and PET scanner used. Finally, none of the studies described, including ours, had enough data from healthy A11 homozygotes to actually test the hypothesis that D2/D3R availability or D2R specific binding is lower in these individuals relative to A11/A12 and A12/A12. To test this hypothesis, given the rare occurrence of homozygosity for A11, future studies must intentionally select enough healthy participants with A1/ A1 to have enough power to detect differences in striatal D2/D3R availability or D2R specific binding between A1/A1, A1/A2, and A2/A2.
In summary, the two independent studies described here showed that DRD2/ANKK1 TaqIA allele status relates to individual differences in striatal D2R specific binding, such that A11 individuals had greater binding relative to A12. The use of the novel D2R specific radioligand and may be displaced by varying levels of endogenous DA (Karimi et al., 2011; Moerlein et al., 1997) . Therefore these studies replicate and extend previous findings from postmortem (Noble et al., 1991; Ritchie & Noble, 2003; Thompson et al., 1997) and PET studies (Jonsson et al., 1999; Pohjalainen et al., 1998; Savitz et al., 2013) performed with D2/D3R radioligands. Our findings also support the hypothesis that the A1 allele (or linked functional variant) may influence risk for substance abuse and psychiatric disorders via D2R, which can be formally tested with mediation analyses.
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